Navigation Links
Karyopharm Therapeutics Announces Oral Presentation at the American College of Rheumatology (ACR) on the use of Selective Inhibitors of Nuclear Export (SINE) CRM1 Antagonists in preclinical models of Systemic Lupus Erythematosus (SLE)
Date:11/12/2012

NATICK, Mass., Nov. 12, 2012 /PRNewswire/ -- Karyopharm Therapeutics Inc., leading the new field of nuclear transport modulators, announces an oral presentation on the use of its SINE CRM1 antagonists for the treatment of systemic lupus erythematosus.

Jennifer Anolik, MD, PhD, Associate Professor of Medicine, Department of Medicine at the University of Rochester (New York), is presenting "Novel nuclear export inhibitors deplete autoreactive plasma cells and protect mice with lupus from nephritis" at the ACR Annual Meeting in Washington DC on November 14 at 12:15 PM in the Concurrent Session on SLE Animal Models.  Dr. Anolik commented, "We are very excited about our findings with Karyopharm's SINE compounds in our mouse lupus models.  These mice develop severe lupus kidney disease which, if untreated, leads to their death.  When we treated the mice with SINE compounds given by mouth, we were able to reduce the level of kidney disease, associated pathogenic autoantibodies, and the plasma cells that produce them.  We are hoping that SINE compounds will be able to move into clinical studies in patients with lupus in the near future."

Dr. Sharon Shacham, Karyopharm's founder, Chief Scientific Officer, and President of research and development commented, "This presentation represents our first public announcement of activity of our novel, oral SINE compounds in an autoimmune disease.  We are particularly excited about Dr. Anolik's work pioneering the use of our compounds to treat mice with severe lupus, and look forward to additional work with her to clarify the key mechanisms responsible for the marked activity she has demonstrated.  We are working with Dr. Anolik and others on plans to evaluate these compounds in humans suffering from lupus and other autoimmune diseases."

About Karyopharm

Founded by Drs. Sharon Shacham and Michael Kauffman in 2009, Karyopharm Therapeutics Inc. has emerged as a leader in the new field of nuclear transport modulators.  The company's selective inhibitors of nuclear export (SINE) function by trapping multiple tumor suppressor and anti-inflammatory proteins in the nucleus, resulting in anti-cancer and anti-inflammatory activity. In collaboration with many academic laboratories, SINEs, targeting the major nuclear exporter CRM1, exert robust anti-cancer and autoimmune disease activity in diverse preclinical models. The lead SINE KPT-330 is now in Phase 1 clinical studies for advanced solid tumor and hematologic malignancies. The related SINE KPT-335 is being evaluated as an oral treatment for dogs with Non-Hodgkin's Lymphoma, one of the most common canine cancers.  The Company is also testing SINEs in other autoimmune diseases, as well as viral and dermatologic disorders. Karyopharm Therapeutics is located in Natick, Massachusetts.

Contact:
Michael Kauffman
(508)975-4821
mkauffman@karyopharm.com


'/>"/>
SOURCE Karyopharm Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Karyopharm Therapeutics Announces Multiple Presentations on Selective Inhibitors of Nuclear Export (SINE) in Solid and Hematologic Malignancy Models and Spontaneous Canine Cancers at the American Association of Cancer Research (AACR) Meeting
2. Karyopharm Therapeutics announces the Publication of Two Preclinical Studies on the Activity of Selective Inhibitors of Nuclear Export (SINE) in Acute Myeloblastic Leukemia (AML)
3. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
4. Nile Therapeutics Reports 2011 Third Quarter Financial Results
5. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
6. Fate Therapeutics Strengthens Its iPSC Platform
7. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
8. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
9. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
10. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
11. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016  Blueprint Bio, a company ... to the medical community, has closed its Series A ... Nunez . "We have received a commitment ... capital we need to meet our current goals," stated ... us the runway to complete validation on the current ...
(Date:6/23/2016)... Francisco, CA (PRWEB) , ... June 23, 2016 ... ... (EDC) software, is exhibiting at the Pennsylvania Convention Center and will showcase its ... Annual conference. ClinCapture will also be presenting a scientific poster on Disrupting Clinical ...
(Date:6/23/2016)... , June 22, 2016  Amgen (NASDAQ: ... of the QB3@953 life sciences incubator to ... health. The shared laboratory space at QB3@953 was created ... a key obstacle for many early stage organizations - ... of the sponsorship, Amgen launched two "Amgen Golden Ticket" ...
(Date:6/22/2016)... 22, 2016 Research and Markets has announced ... report to their offering. ... from $29.3 billion in 2013. The market is expected to grow ... 2015 to 2020, increasing from $50.6 billion in 2015 to $96.6 ... during the forecast period (2015 to 2020) are discussed. As well, ...
Breaking Biology Technology:
(Date:5/20/2016)... , May 20, 2016  VoiceIt is ... partnership with VoicePass. By working together, ... experience.  Because VoiceIt and VoicePass take slightly different ... engines increases both security and usability. ... excitement about this new partnership. "This ...
(Date:5/12/2016)... 2016 WearablesResearch.com , a brand of ... results from the Q1 wave of its quarterly wearables ... consumers, receptivity to a program where they would receive ... insurance company. "We were surprised to see ... Michael LaColla , CEO of Troubadour Research, "primarily because ...
(Date:5/3/2016)...  Neurotechnology, a provider of high-precision biometric identification ... Identification System (ABIS) , a complete system for ... can process multiple complex biometric transactions with high ... face or iris biometrics. It leverages the core ... MegaMatcher Accelerator , which have been used in ...
Breaking Biology News(10 mins):